Actuate Therapeutics replaces auditor after KMJ joins Crowe; prior reports cite going concern and material weakness

ACTUATE THERAPEUTICS, INC.

KMJ Corbin & Company LLP resigned as auditor on Aug 19, 2024; Crowe LLP appointed same day.
KMJ audit reports for FY2023 and FY2022 included a going-concern explanatory paragraph about substantial doubt.
Company reported a material weakness in internal control over financial reporting due to inadequate review of clinical trial expense accruals.
No disagreements between Company and KMJ on accounting principles or auditing scope.
KMJ's professional staff joined Crowe LLP on May 20, 2024; change is related to that merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.